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Sarcoidosis is a multisystem noncaseating granulomatous dis-
ase of unknown etiology. Pathologically, this granulomatous
nﬂammation is characterized by accumulation of monocytes,
acrophages, and activated T-lymphocytes, and there is evidence
or a predominant type 1 T-helper cell response, resulting in an
mbalance involving type 1 and type 2 helper-T cell cytokines
nd accelerated inﬂammation in sarcoidosis. It is most commonly
bserved in the lungs, but other organ systems (lymph nodes,
kin, eyes, heart, nerves, and renal and endocrine systems) are also
nvolved. Among them, cardiac sarcoidosis (CS) occurs in 20–27%
f sarcoidosis patients in the USA and may  occur more frequently
n as many as 58% of patients in Japan [1–3] and has a poor outcome
ecause of congestive heart failure, atrioventricular (AV) block, and
entricular tachyarrhythmias (VT). Therapy with corticosteroids or
ther immunosuppressant agents has been reported to be effec-
ive to prevent progression of these cardiac conditions and improve
urvival in patients with CS [4]. The mechanism of action of corti-
osteroids in CS is unknown, but it is thought that corticosteroids
ould relieve the progression of inﬂammation and ﬁbrosis through
e-establishing a normal balance between locally produced type 1
nd type 2 helper-T cell cytokines [5], and thus early initiation of
orticosteroids is recommended in CS patients.
AV block is the most common arrhythmia in CS and is reported
n 26–67% of patients [6] due to involvement of the basal septum by
 scar tissue or granulomas or the involvement of the nodal artery
ausing ischemia in the conduction system. Corticosteroids have
een reported to be considered effective for the recovery of this AV
lock but not VT events in some CS patients (most of them were
ublished from Japan) [7–9]. Kato et al. reported that recovery of
V conduction was observed in 4 of 7 treated patients (57.1%) and
ll 13 untreated patients had persistent complete AV block after
9.4 months [8]. Banba et al. also reported that recovery of AV con-
uction was observed in 5 of 9 treated patients (56.6%), in whom
V conduction improved to normal in 3 patients and to transient
rst-degree AV block in 2 patients after a relatively short period of months [7]. In the recent systematic analysis review [10], 27 of
7 treated patients (47.4%) with AV block recovered AV conduction
ut none of the untreated patients improved. However, adequate
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dosage and long-term efﬁcacy of corticosteroids on AV conduction
system have not been proven to date.
The results of the study by Yodogawa [11] published in this
journal have indicated the interesting possibility that corticoste-
roid therapy is effective not only for the recovery of AV conduction,
but also to maintain AV conduction. They reported that 7 of 15 CS
patients (46.7%) with complete AV block recovered to normal con-
duction or ﬁrst-degree AV conduction after corticosteroids (acute
dose of 30 mg/day and maintenance dose of 5–10 mg/day) and this
effect was sustained at least during a mean follow-up period of 7.1
years. They also reported that the recovery group had a higher left
ventricular ejection fraction (69.4% vs. 44.1%) and a higher preva-
lence of advanced AV block (87.5% vs. 28.6%), indicating that early
initiation of corticosteroids should be recommended in CS. Similar
results were also reported by Banba et al. that positive Gallium-67
uptake was correlated with new onset of high-grade AV block but
not VT episodes (80% in AV block vs. 14% in VT, p < 0.02) [7]. These
retrospective data indicates that AV block in CS develops mainly
during the early, active, and inﬂammatory phase of the disease,
and there is relatively higher possibility of AV conduction recovery
after corticosteroid therapy. However, in view of the unpredictable
response, all patients diagnosed with CS should receive pacemaker
implantation.
Unlike in the case of AV block, the effect of corticosteroids on
VT was  not consistent in the previous reports. A favorable effect
was reported by Futamatsu et al. [12] and Yodogawa et al. (the
patients were included in this study) [9], but amiodarone was
started concomitantly in the former report and only the reduction
of ventricular premature contractions and nonsustained VT in the
subgroup of patients with left ventricular ejection fraction >35% in
the latter group. Because it appears likely that in many cases VT is
related to scar formation, corticosteroids might have little beneﬁ-
cial effect on VT events. Thus, CS patients with VT should receive
an implantable cardioverter deﬁbrillator.
In conclusion, although the number of patients in this study was
small and a further prospective registry or randomized study is
needed to reach a deﬁnitive conclusion, Yodogawa et al. have pro-
vided important clinical evidence suggesting that early initiation
of corticosteroid therapy is effective for the recovery of AV block
in CS patients and may  be a possible therapeutic strategy for some
selected CS patients.
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